Literature DB >> 2994141

Melatonin, cortisol and ACTH in patients with major depressive disorder and healthy humans with special reference to the outcome of the dexamethasone suppression test.

J Beck-Friis, J G Ljunggren, M Thorén, D von Rosen, B F Kjellman, L Wetterberg.   

Abstract

The 24 hr profiles of melatonin and cortisol in serum, morning levels of ACTH in plasma, and the dexamethasone suppression test (DST) were investigated in 32 acutely ill patients with a RDC diagnosis of major depressive disorder, 24 patients with a history of longlasting unipolar or bipolar major depressive disorder studied in remission, and 33 healthy subjects. A significant decrease in maximum nocturnal melatonin level (MTmax) was found in the acutely ill depressed patients with abnormal DST compared to both those with normal DSTs and the healthy subjects. The MTmax levels were unaltered when these patients were reinvestigated in remission. A decrease of MTmax was also seen in the group of unipolar and bipolar patients studied in remission. Low nocturnal melatonin is proposed to be a trait marker for major depressive disorder and depressive states with abnormalities in the hypothalamic--pituitary--adrenal (HPA) axis. A significant decrease of ACTH levels at 0800 hr after dexamethasone administration the preceding evening was found in the healthy subjects, the unipolar--bipolar patients in remission, and the acutely ill depressed patients with normal DSTs, but was not found in the acutely ill depressed patients with abnormal DSTs. These findings support the hypothesis that pituitary ACTH regulation is altered in depressed patients with abnormal DST. Morning plasma ACTH before the administration of dexamethasone did not significantly differ between the acutely ill depressed patients with abnormal DSTs, normal DSTs, the patients with unipolar--bipolar disease in remission, or the healthy subjects. Thus, the abnormalities in the HPA axis in depresséd patients are proposed to be due to a hypersecretion of corticotrophin releasing factor (CRF) with a subsequent stimulus-induced pituitary desensitization. A significant decrease of melatonin after dexamethasone was seen at 0800 hr in the unipolar--bipolar patients in remission as well as in the healthy subjects, at 1600 hr and 2200 hr in the acutely ill depressed patients in remission, but not at 0800 hr in the acutely ill depressed patients in relapse. A significant regression was found between MTmax levels and the degree of non-suppression of cortisol at 0800 hr in the DST in the acutely ill depressed patients both in relapse and in remission. Melatonin thus is proposed to be an inhibiting factor for CRF during depression. A trend to a phase-advance of cortisol nadir and melatonin peak was seen in the acutely ill depressed patients with abnormal DST, possibly indicating an involvement of the suprachiasmatic nuclei in the hypothalamus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2994141     DOI: 10.1016/0306-4530(85)90055-1

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  21 in total

Review 1.  Melatonin, circadian rhythms, and the clock genes in bipolar disorder.

Authors:  Sara Dallaspezia; Francesco Benedetti
Journal:  Curr Psychiatry Rep       Date:  2009-12       Impact factor: 5.285

Review 2.  Dissection of glucocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis by gene targeting in mice.

Authors:  Gloria Laryea; Lisa Muglia; Melinda Arnett; Louis J Muglia
Journal:  Front Neuroendocrinol       Date:  2014-09-27       Impact factor: 8.606

Review 3.  Psychoneuroendocrine research in depression. I. Hormone levels of different neuroendocrine axes and the dexamethasone suppression test.

Authors:  R Rupprecht; K P Lesch
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

Review 4.  Chronobiology of bipolar disorder: therapeutic implication.

Authors:  Sara Dallaspezia; Francesco Benedetti
Journal:  Curr Psychiatry Rep       Date:  2015-08       Impact factor: 5.285

5.  Circadian profile of serum melatonin in patients with Cushing's syndrome or acromegaly.

Authors:  M Terzolo; A Piovesan; A Alì; A Codegone; A Pia; G Reimondo; M Torta; P Paccotti; G Borretta; A Angeli
Journal:  J Endocrinol Invest       Date:  1995-01       Impact factor: 4.256

Review 6.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Clinical aspects of the melatonin action: impact of development, aging, and puberty, involvement of melatonin in psychiatric disease and importance of neuroimmunoendocrine interactions.

Authors:  F Waldhauser; B Ehrhart; E Förster
Journal:  Experientia       Date:  1993-08-15

8.  Urine melatonin in alcoholic patients: a marker of alcohol abuse?

Authors:  G Murialdo; U Filippi; P Costelli; S Fonzi; P Bo; A Polleri; F Savoldi
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

9.  Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder.

Authors:  Virginia Soria; Erika Martínez-Amorós; Geòrgia Escaramís; Joaquín Valero; Rosario Pérez-Egea; Cecilia García; Alfonso Gutiérrez-Zotes; Dolors Puigdemont; Mònica Bayés; José M Crespo; Lourdes Martorell; Elisabet Vilella; Antonio Labad; Julio Vallejo; Víctor Pérez; José M Menchón; Xavier Estivill; Mònica Gratacòs; Mikel Urretavizcaya
Journal:  Neuropsychopharmacology       Date:  2010-01-13       Impact factor: 7.853

10.  Signatures of depression in non-stationary biometric time series.

Authors:  Milka Culic; Biljana Gjoneska; Hiie Hinrikus; Magnus Jändel; Wlodzimierz Klonowski; Hans Liljenström; Nada Pop-Jordanova; Dan Psatta; Dietrich von Rosen; Björn Wahlund
Journal:  Comput Intell Neurosci       Date:  2009-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.